What is the Geographic Atrophy Market and why is it important?

The geographic atrophy (GA) market refers to the global industry focused on treatments, therapies, and diagnostic solutions for geographic atrophy, a severe form of age-related macular degeneration (AMD). GA leads to progressive vision loss and significantly impacts the quality of life for millions of people worldwide, especially older adults.

The importance of this market lies in the growing need for effective therapies, as GA has historically been considered an untreatable condition. With new drug approvals, advanced diagnostics, and supportive healthcare infrastructure, the market has become a critical focus for pharmaceutical companies, healthcare providers, and patients.

What is the current size of the Geographic Atrophy Market?

According to the latest data, the geographic atrophy market was valued at USD 24.10 Billion in 2024. The market is projected to grow steadily at a CAGR of 5.70% between 2025 and 2034, reaching USD 41.95 Billion by 2034.

This strong growth trajectory reflects both the increasing prevalence of GA and advancements in therapeutic options across the 8 major markets.

Which factors are driving the growth of this market?

Several factors are fueling the expansion of the GA market, including:

  • Rising prevalence of GA due to aging populations worldwide.

  • Regulatory approvals of new therapeutic agents, which provide hope for patients and drive demand.

  • Increased awareness and diagnosis of age-related macular degeneration.

  • Investment in research and development (R&D), leading to innovative therapies and improved patient outcomes.

  • Improved healthcare infrastructure in both developed and emerging markets.

What are the major trends in the Geographic Atrophy Market?

Some key trends shaping the market include:

  • Breakthrough drug approvals that are expanding treatment options.

  • Shift toward personalized medicine, with therapies tailored to patient needs.

  • Growing role of advanced imaging technologies for early detection and monitoring of GA.

  • Rising partnerships and collaborations among biotech firms and pharmaceutical giants to accelerate R&D.

  • Increased patient-centric approaches, focusing on quality of life and long-term management.

Request Your Complimentary Report Sample & TOC Now

How is the market segmented?

The geographic atrophy market can be segmented across several key categories:

  • By Treatment Type:

    • Complement inhibitors

    • Anti-VEGF therapies

    • Others (including pipeline therapies)

  • By Distribution Channel:

    • Hospital pharmacies

    • Retail pharmacies

    • Online pharmacies

  • By Region:

    • North America (United States, Canada)

    • Europe (EU-4, United Kingdom)

    • Asia-Pacific

    • Others (emerging markets with growing healthcare access)

This segmentation highlights how the market reaches patients through multiple channels and regions.

Who are the key players in the Geographic Atrophy Market?

The GA market is highly competitive, with both established pharmaceutical companies and emerging biotech firms actively contributing. Key players include:

  • Apellis Pharmaceuticals

  • Iveric Bio (an Astellas company)

  • Roche

  • Novartis AG

  • Regeneron Pharmaceuticals, Inc.

  • Janssen Pharmaceuticals

  • Other biotech firms focused on ophthalmology R&D

These companies are investing heavily in clinical trials, regulatory approvals, and commercialization of novel therapies.

What challenges does the market face?

Despite strong growth potential, the GA market faces some significant hurdles:

  • High cost of treatment, which may limit patient access.

  • Complex regulatory processes, delaying the availability of new drugs.

  • Limited awareness in certain regions, leading to underdiagnosis and undertreatment.

  • Unmet clinical needs, as many therapies focus on slowing progression rather than offering a complete cure.

What is the future outlook for the Geographic Atrophy Market?

The future of the geographic atrophy market looks promising. With continued R&D, new drug approvals, and growing awareness, patients will have access to more effective treatment options in the coming years. By 2034, the market is expected to reach USD 41.95 Billion, signaling strong industry potential.

Innovations in gene therapy, stem cell research, and targeted biologics are likely to reshape treatment landscapes, offering hope for better disease management and improved patient outcomes.

FAQs About the Geographic Atrophy Market

Is geographic atrophy completely curable?
No, GA is not yet completely curable. Current therapies mainly slow disease progression, but ongoing research may bring more effective solutions in the future.

Which treatment works the fastest for GA?
Complement inhibitors have shown promising results in clinical trials, but effectiveness varies by patient. It’s best determined by an ophthalmologist.

Which region dominates the GA market?
North America currently leads the geographic atrophy market, driven by strong healthcare systems, high diagnosis rates, and early access to new treatments.

Why is the GA market growing so quickly?
Aging populations, rising prevalence, and breakthrough therapies are the main reasons behind its strong growth.